Platform for in vitro airborne inhalation testing

04:1313 months ago

The air-liquid interface (ALI) technique uses lung cells cultured on a tiny polymer membrane in a cup. On one side of the membrane is a liquid containing the medium necessary for the cells to survive, while the other side is in contact with air. This is similar to the situation in the human lung. The compound to be tested is administered via an aerosol, vapor, or gas to mimic the situation in human lungs. By monitoring different parameters in the cell model before and after the compound is added, it is possible to measure the effects on lung cells. Depending on the test to be carried out, the lung cells can come from different regions in the respiratory tract and even from a variety of people, including individuals who smoke a lot or have specific diseases such as chronic obstructive pulmonary disease or asthma.

In vitro ALI inhalation testing adds value for e.g. pre-clinical trials and research in the pharmaceutical industry and testing (new) compounds for the chemical sector and beyond. The advantages of ALI inhalation testing are that it is a non-animal method, it reduces the use of in vivo experiments, pre-clinical testing with human-derived cell models is more realistic and limits clinical trial failures and it provides faster and more efficient testing of compound

Related

Five simple tricks for making your own video for TPI.tv
TPI.tv videos

Five simple tricks for making your own video for TPI.tv

This video shows you how to make a video yourself. It's really not that difficult! See also https://tpi.tv/how-to-submit for additional information.
01:234 years ago
EURL ECVAM
Projects and initiatives
HealthInnovationPolicy

EURL ECVAM

The EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) promotes and facilitates the use of non-animal methods in testing and research. It validates, disseminates and shares knowledge on the 3Rs (Replacement, Reduction and Refinement of animal experiments). In this video, Raffaella Corvi explains what EURL ECVAM does in the field of safety testing of chemicals while reducing laboratory animal testing. Watch the accessible version of the video here (https://audiovisual.ec.europa.eu/en/video/I-230374). ©European Union, 2021
02:3353 days ago
Stem cell derived Vessels-on-Chip to study brain disorders
Innovation examples
HealthIn vitroOrgan-on-Chip

Stem cell derived Vessels-on-Chip to study brain disorders

Dennis Nahon is a PhD candidate in the Department of Anatomy and Embryology at the Leiden University Medical Center. In his research, under supervision of Dr. Valeria Orlova (https://www.orlovalab.com/) and Prof. Dr. Christine Mummery, he aims to mimic a blood vessel in the brain by combining different stem cell derived cell types, in a 3D Vessel-on-Chip model. Here, an example of these in vitro blood vessels is shown in which certain brain cells known as astrocytes (in white) interact with the blood vessels (in red). This model paves the way for investigating brain vessels outside the human body, while reducing the need for animal models.
01:532 months ago
 From 2D hiPSC culture to developing a 3D vessel-on-chip
Innovation examples
In vitroOrgan-on-Chip

From 2D hiPSC culture to developing a 3D vessel-on-chip

Theano Tsikari is a 2nd year PhD student at the Orlova group at LUMC. As part of the LymphChip consortium, her project focuses on the development of immunocompetent organ-on-chip models of the cardiovascular system, and especially the integration of tissue-resident macrophages and lymphatic vasculature using human induced pluripotent stem cells. In this video, you can follow her as she presents you the backbone of her project, a 3D hiPSC-derived vessel-on-chip model, that has been previously developed in the Orlova group and can be employed for the generation of advanced in vitro models of vascular diseases.
01:292 months ago